Name: Wang Peng  
Title: M.D., Associate Professor

Education & Professional Experience  

2013-Present, Associate professor, Dept. of Integrative Oncology, Fudan University Shanghai Cancer Center;
2009-2013, Attending Doctor, Dept. of Integrative Oncology, Fudan University Shanghai Cancer Center;
2008-2009, Resident Doctor, Dept. of Integrative Oncology, Fudan University Shanghai Cancer Center;
2003-2008, M.D&Ph.D, Shanghai medical college, Fudan University.


(a)Minimally invasive therapy including radiofrequency ablation, High intensity focused ultrasound (HIFU), transcatheter arterial chemoembolization (TACE) for pancreatic and liver cancer.
(b)Traditional Chinese medicine for cancer treatment.

Research   (a)Translational research and clinical trials in pancreatic and liver cancer
Principal Investigator, National Science Foundation of China (81001061and 81370068);
Principal Investigator, Shanghai Nature Science Fund, Shanghai, China (09ZR1406800);
Principal Investigator, Doctoral Programs Foundation of the Ministry of Education of China (20090071120076);
Principal Investigator, Shanghai Science and Technology Committee Rising-Star Program (11QA1401300);
Principal Investigator, Medical Talents Training Program of the Health Bureau of Shanghai (XYQ2011008);
Principal Investigator, Fudan University Zhuo-Xue Program.

Original articles:
(1)Qi Q, Geng Y, Sun M, Wang P*, Chen Z*. Clinical implications of systemic inflammatory response markers as independent prognostic factors for advanced pancreatic cancer. Pancreatology 2015;15(2):145-50 [*Corresponding author]
(2)Qi Q, Geng Y, Sun M, Chen H, Wang P*, Chen Z*. Hyperfibrinogen is associated with the systemic inflammatory response and predicts poor prognosis in advanced pancreatic cancer. Pancreas 2015; In press [*Corresponding author]
(3)Chen L, Fan J, Chen H, Meng Z, Chen Z, Wang P*, Liu L*. The IL-8/CXCR1 axis is associated with cancer stem cell-like properties and correlates with clinical prognosis in human pancreatic cancer cases. Sci Rep 2014 ; 4, 5911. [*Corresponding author]
(4)Chen L, Qu C, Chen H, Xu L, Qi Q, Luo J, Wang K, Meng Z, Chen Z*, Wang P*, Liu L*. Chinese herbal medicine suppresses invasion-promoting capacity of cancer-associated fibroblasts in pancreatic cancer. PLOS One 2014 ; 9(4) : e96177 [*Corresponding author]
(5)Wang P, Chen L, Zhang J, Chen H, Fan J, Wang K, Luo J, Chen Z, Meng Z, Liu L. Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1. Oncogene. 2014; 33(4):514-24.
(6)Wang P, Zhang J, Zhang L, Zhu Z, Fan J, Chen L, Zhuang L, Luo J, Chen H, Liu L, Chen Z, Meng Z. MicroRNA 23b regulates autophagy associated with radioresistance of pancreatic cancer cells. Gastroenterology. 2013;145(5):1133-1143.e12.
(7)Wang P, Zhuang L, Zhang J, Fan J, Luo J, Chen H, Wang K, Liu L, Chen Z, Meng Z. The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL. Mol Oncol. 2013;7(3):334-45.
(8)Zhang J#, Wang P #, Ouyang H, Yin J, Liu A, Ma C, Liu L. Targeting cancer-related inflammation with Chinese herbal medicine inhibits epithelial-to-mesenchymal transition in pancreatic cancer. PLoS One 2013; 8 (7):e70334 [#Co-first]
(9)Chen Z, Chen LY, Wang P*, Dai HY, Gao S, Wang K. Tumor microenvironment varies under different TCM ZHENG models and correlates with treatment response to herbal medicine Evid Based Complement Alternat Med. 2012; 2012: 635702 [*Corresponding]
(10)Ouyang H#, Wang P#, Meng Z, Chen Z, Yu E, Jin H, Chang D, Liao Z, Cohen L, Liu L. Multimodality treatment of pancreatic cancer with liver metastases using chemotherapy, radiation therapy, and/or Chinese herbal medicine. Pancreas 2011; 40(1):120-5. [#Co-first]
(11)Li H#, Wang P#, Gao Y, Zhu X, Meng Z. Na+/K+-ATPase α3 mediated the sensitivity of hepatocellular carcinoma cells to bufalin. Oncol Rep 2011; 25(3) :825-30. [#Co-first]
(12)Wang P, Chen Z, Meng ZQ, Fan J, Luo JM, Liang M, Lin JH, Zhou ZH, Chen H, Wang K, Shen YH, Xu ZD, Liu LM.Ski acts as therapeutic target of Qingyihuaji formula in the treatment of SW1990 pancreatic cancer. Integr Cancer Ther 2010; 9(1) :50-8.
(13)Wang P, Chen Z, Meng ZQ, Fan J, Luo JM, Liang M, Lin JH, Zhou ZH, Chen H, Wang K, Shen YH, Xu ZD, Liu LM. Dual role of Ski in pancreatic cancer cells: Tumor-promoting versus metastasis-suppressive function. Carcinogenesis. 2009; 30(9):1497-506.
(14)Wang P, Fan J, Chen Z, Meng ZQ, Luo JM, Lin JH, Zhou ZH, Chen H, Wang K, Xu ZD, Liu LM. Low-level expression of Smad7 correlates with lymph node metastasis and poor prognosis in patients with pancreatic cancer. Ann Surg Oncol. 2009 ; 16(4) :826-35.
(15)Wang P, Meng ZQ, Chen Z, Lin JH, Ping B, Wang LF, Wang BH, Liu LM. Diagnostic value and complications of fine needle aspiration for primary liver cancer and its influence on the treatment outcome-a study based on 3011 patients in China. Eur J Surg Oncol. 2008;34(5):541-6.
(16)Wang P, Meng ZQ, Chen Z, Lin JH, Zhou ZH, Chen H, Wang K, Shen YH, Zhu ZF, Zhao GF, Fu H, Liu LM. Survival rate of pancreatic cancer in elderly patients. Hepatogastroenterology. 2008; 55(82-83):681-6.

Invited reviews:
(1)Wang P, Zhang L, Chen Z, Meng Z. MicroRNA targets autophagy in pancreatic cancer cells during cancer therapy. Autophagy. 2013;9(12):2171-2.
(2)Wang P*, Chen Z. Traditional Chinese Medicine ZHENG and OMICS Convergence: A Systems Approach to Post-Genomics Medicine in a Global World. OMICS 2013;17(9):451-9. [*Corresponding author]
(3)Chen Z, Wang P*. Clinical distribution and molecular basis of traditional Chinese medicine ZHENG in cancer. Evid Based Complement Alternat Med. 2012; 2012: 783923 [*Corresponding author]


2014, Excellent Young scholar in Fudan University Shanghai Cancer Center;
2013, Excellent Young Teacher in Fudan University;
2012, Excellent Scholar in Fudan University;
2011, Rising-Star of Shanghai Science and Technology Committee;
2011, Medical Talents of the Health Bureau of Shanghai.

Out-patient Schedule  

Friday afternoon